SHR- A1811
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gynaecological Malignancies
Conditions
Gynaecological Malignancies
Trial Timeline
Jul 10, 2023 → Jun 15, 2026
NCT ID
NCT05896020About SHR- A1811
SHR- A1811 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Gynaecological Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05896020. Target conditions include Gynaecological Malignancies.
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05896020 | Phase 2 | Recruiting |
Competing Products
1 competing product in Gynaecological Malignancies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ceralasertib + Olaparib + Durvalumab | AstraZeneca | Phase 2 | 39 |